SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9479	Companies
185510	Keywords
117899	Articles
99364	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 12/11/2024 at 07:00, 11 months 25 days ago

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Sanofi's two combination vaccine candidates targeting influenza and COVID-19 granted Fast Track designation in the US. Candidates combine licensed vaccines to assess safety and immunogenicity in older adults

COVID-19 Sanofi Influenza Combination Vaccine Fast Track Designation
BRIEF

published on 12/09/2024 at 20:11, 11 months 26 days ago

Sarclisa Combinations Show Promise in Multiple Myeloma Treatment

Clinical Study Multiple Myeloma Sarclisa MRD Negativity Treatment Efficacy
PRESS RELEASE

published on 12/09/2024 at 20:06, 11 months 26 days ago

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New data presented at ASH demonstrates significant clinical benefit with Sarclisa-based combinations in newly diagnosed multiple myeloma patients, highlighting deep and durable responses and improved outcomes

Multiple Myeloma Sarclisa ASH MRD Negativity Clinical Benefit
BRIEF

published on 12/07/2024 at 17:35, 11 months 29 days ago

Rilzabrutinib: Promising Advances in the Treatment of IPT

Security Efficiency Phase III Rilzabrutinib TPI
PRESS RELEASE

published on 12/07/2024 at 17:30, 11 months 29 days ago

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted

Phase 3 Study Rilzabrutinib ITP BTK Inhibitor Patient Benefit
BRIEF

published on 12/06/2024 at 07:35, 11 months 30 days ago

Sanofi Publishes Revised Financial Statements Excluding Opella

Financial Statements Biopharma Sanofi 2024 Results Opella
PRESS RELEASE

published on 12/06/2024 at 07:30, 11 months 30 days ago

Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025

Sanofi Discontinued Operations Opella Revised Financial Statements Biopharma Company
PRESS RELEASE

published on 10/25/2024 at 07:30, 1 year 1 month ago

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
BRIEF

published on 10/24/2024 at 14:05, 1 year 1 month ago

Positive Phase 3 Data for Dupixent in Chronic Spontaneous Urticaria Released

Dupixent Chronic Spontaneous Urticaria Phase 3 Data ACAAI Presentation Treatment Innovation
PRESS RELEASE

published on 10/24/2024 at 14:00, 1 year 1 month ago

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent phase 3 data in chronic spontaneous urticaria presented at ACAAI shows reduced itch and hive activity, potential new treatment for CSU patients

Dupixent Chronic Spontaneous Urticaria ACAAI Phase 3 Data Targeted Treatment

Accesswire

Published on 12/05/2025 at 17:15, 51 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 6 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 2 hours 6 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 2 hours 21 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 2 hours 31 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:51, 14 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 20 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 6 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 41 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 56 minutes ago

Reorganization of the Eckert & Ziegler Executive Board

Les Echos

Published on 12/05/2025 at 17:18, 48 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 2 hours 55 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 9 hours 21 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE